Literature DB >> 23722435

Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay.

Norman K Fry1, David J Litt1, John Duncan1, Lalita Vaghji1, Lenesha Warrener2, Dhanraj Samuel2, Nick Andrews3, Anthony Harnden4, Timothy G Harrison1.   

Abstract

Recent vaccination with pertussis vaccine can confound serological and oral fluid (OF) assays targeting anti-pertussis toxin (anti-PT) IgG antibodies as a marker of recent infection. This study sought to establish the minimum potentially confounding time period based on experimental data to assist interpretation from such samples submitted from UK subjects for pertussis diagnosis. Anti-PT IgG antibody response and decay were measured post-vaccination using a modified OF IgG antibody-capture ELISA (GACELISA). Data were obtained from 72 infants after the third acellular pertussis vaccine dose in the primary schedule (4 months of age) and from 119 children after the single dose at preschool age (3 years 4 months to 5 years 8 months of age). Specimens were taken at approximately 1 month intervals for 9 months post-primary immunization (third dose) and 13 months post-preschool booster (PSB). The modified GACELISA demonstrated a sensitivity of 52/56 (92.9 %: 95 % CI 82.7-98.0) and a specificity of 120/128 (93.8 %: 95 % CI 88.0-97.3) and showed good agreement with the National Reference Laboratory standard anti-PT IgG serum ELISA (rank correlation = 0.80) and the original OF assay (rank correlation = 0.79). Modelling of the decline in antibody titres showed a reduction of 54 % and 34 % for each doubling of time after day 14 for the post-third primary dose and post-PSB subjects, respectively. These data suggest that the minimum confounding time period is approximately 300 days for samples obtained post-primary immunization and at least 3 years for samples submitted from UK children following immunization with the PSB. These data will greatly assist the interpretation of single high diagnostic anti-PT IgG titres by allowing an estimate of the positive predictive value, when the number of days post-immunization and prevalence are known or assumed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23722435     DOI: 10.1099/jmm.0.062000-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  10 in total

Review 1.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

Review 2.  Laboratory Diagnosis of Pertussis.

Authors:  Anneke van der Zee; Joop F P Schellekens; Frits R Mooi
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 3.  Symptomatic treatment of the cough in whooping cough.

Authors:  Kay Wang; Silvana Bettiol; Matthew J Thompson; Nia W Roberts; Rafael Perera; Carl J Heneghan; Anthony Harnden
Journal:  Cochrane Database Syst Rev       Date:  2014-09-22

4.  Oral fluid testing for pertussis, England and wales, june 2007-august 2009.

Authors:  Helen Campbell; Gayatri Amirthalingam; Norman K Fry; David Litt; Timothy G Harrison; Karen Wagner; Natasha S Crowcroft; Elizabeth Miller
Journal:  Emerg Infect Dis       Date:  2014-06       Impact factor: 6.883

5.  Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction.

Authors:  Gayatri Amirthalingam; Helen Campbell; Sonia Ribeiro; Norman K Fry; Mary Ramsay; Elizabeth Miller; Nick Andrews
Journal:  Clin Infect Dis       Date:  2016-12-01       Impact factor: 9.079

6.  Impact of age and vaccination history on long-term serological responses after symptomatic B. pertussis infection, a high dimensional data analysis.

Authors:  Inonge van Twillert; Axel A Bonačić Marinović; Betsy Kuipers; Jacqueline A M van Gaans-van den Brink; Elisabeth A M Sanders; Cécile A C M van Els
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

7.  Investigation of a pertussis outbreak and comparison of two acellular booster pertussis vaccines in a junior school in South East England, 2019.

Authors:  Elise Tessier; Helen Campbell; Sonia Ribeiro; Nick Andrews; Julia Stowe; Margot Nicholls; Jaime Morgan; David Litt; Norman K Fry; Gayatri Amirthalingam
Journal:  Euro Surveill       Date:  2021-03

8.  Impact of the COVID-19 pandemic on Bordetella pertussis infections in England.

Authors:  Elise Tessier; Helen Campbell; Sonia Ribeiro; Yuma Rai; Simon Burton; Partho Roy; Norman K Fry; David Litt; Gayatri Amirthalingam
Journal:  BMC Public Health       Date:  2022-02-28       Impact factor: 3.295

9.  Whooping cough in school age children presenting with persistent cough in UK primary care after introduction of the preschool pertussis booster vaccination: prospective cohort study.

Authors:  Kay Wang; Norman K Fry; Helen Campbell; Gayatri Amirthalingam; Timothy G Harrison; David Mant; Anthony Harnden
Journal:  BMJ       Date:  2014-06-24

10.  The Use of Innovative Two-Component Cluster Analysis and Serodiagnostic Cut-Off Methods to Estimate Prevalence of Pertussis Reinfections.

Authors:  Inonge van Twillert; Axel A Bonačić Marinović; Jacqueline A M van Gaans-van den Brink; Betsy Kuipers; Guy A M Berbers; Nicoline A T van der Maas; Theo J M Verheij; Florens G A Versteegh; Peter F M Teunis; Cécile A C M van Els
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.